Liver Cirrhosis

Mesenchymal Stem Cells (MSCs) are being studied in liver cirrhosis to explore whether their regenerative and immune-modulating properties may help support liver health. Current research evaluates biological signals such as anti-fibrotic activity and tissue repair. 

Liver cirrhosis is a progressive condition caused by long-term liver damage, often due to hepatitis, alcohol use, or metabolic disease. It leads to scarring, impaired function, and can progress to failure where transplantation remains the only curative option. 

Although findings are early, MSC investigations are expanding the scientific understanding of potential cell-based approaches in hepatology and regenerative medicine. 

Clinical Trials

Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial — Ming Shi, et al.


 

Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients — Ming Shi, et al.


 

Bone Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3: A Phase I-II Randomized Clinical Trial — Fernando Comunello Schacher, et al.


 

Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial — Federica Casiraghi, et al.


 

Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial — Pedram Kharaziha, et al.


 

A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection — Ming Shi, et al.